Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
06 January 2014Website:
http://www.akaritx.comNext earnings report:
27 September 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 01 Jul 2024 20:05:06 GMTDividend
Analysts recommendations
Institutional Ownership
AKTX Latest News
Agreed to merge with Peak Bio in a definitive agreement, anticipated to be finalized in the third quarter of 2024.
Akari Therapeutics, Plc will be presenting new pre-clinical data on investigational long-acting PAS-nomacopan, including its effect on electroretinography (ERG) testing in a blue light model, at the upcoming ARVO 2024 Annual Meeting in Seattle. Chief Scientific Officer Miles Nunn will provide an overview of the data in a poster presentation on Sunday, May 5 from 1:00 to 2:45 pm PT.
NEW YORK and BOSTON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that President and CEO Rachelle Jacques will present a company overview for in-person and virtual attendees at Biotech Showcase taking place in San Francisco, CA January 8-10, 2024, adjacent to the J.P. Morgan Healthcare Conference 2024. Akari management will attend one-on-one meetings during the conferences.
BOSTON and LONDON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the company will participate in the Emerging Growth Conference being held October 4 and 5, 2023. President and CEO Rachelle Jacques will present an overview of the company and its lead asset nomacopan, a bispecific inhibitor of complement C5 and leukotriene B4 (LTB4), on October 4, 2023 from 11:25 am to 11:55 am ET.
Penny stocks hold a distinctive charm for many investors. Amidst fluctuating market trends and the occasional downturn, there's often a group of these low-cost stocks surging in value.
There's something special about penny stocks. Even when the stock market is down, like it is today, you're likely to find at least a handful exploding higher.
What type of business is Akari Therapeutics?
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
What sector is Akari Therapeutics in?
Akari Therapeutics is in the Healthcare sector
What industry is Akari Therapeutics in?
Akari Therapeutics is in the Biotechnology industry
What country is Akari Therapeutics from?
Akari Therapeutics is headquartered in United States
When did Akari Therapeutics go public?
Akari Therapeutics initial public offering (IPO) was on 06 January 2014
What is Akari Therapeutics website?
https://www.akaritx.com
Is Akari Therapeutics in the S&P 500?
No, Akari Therapeutics is not included in the S&P 500 index
Is Akari Therapeutics in the NASDAQ 100?
No, Akari Therapeutics is not included in the NASDAQ 100 index
Is Akari Therapeutics in the Dow Jones?
No, Akari Therapeutics is not included in the Dow Jones index
When does Akari Therapeutics report earnings?
The next expected earnings date for Akari Therapeutics is 27 September 2024